Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.

ABSTRACT:

Rationale & objective

In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes. This analysis explores the efficacy and safety of finerenone in Hispanic patients.

Study design

Post hoc analysis of the FIDELITY prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD randomized control trials.

Setting & participants

Patients with type 2 diabetes and CKD (urinary albumin-to-creatinine ratio [UACR] of ≥30 to <300 mg/g and estimated glomerular filtration rate [eGFR] of ≥25-≤90 mL/min/1.73 m², or UACR of ≥300 to ≤5,000 and eGFR of ≥25 mL/min/1.73 m²) on optimized renin-angiotensin system blockade.

Intervention

Finerenone or placebo.

Outcomes

Cardiovascular composite (ca

SUBMITTER: Rosas SE 

PROVIDER: S-EPMC10514441 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature